| Full text | |
| Author(s): |
Total Authors: 3
|
| Affiliation: | [1] Hosp Israelita Albert Einstein, Albert Einstein Res & Educ Inst, 627 Albert Einstein Ave, Bldg A, Sao Paulo, SP - Brazil
[2] Univ Fed Sao Paulo, Nephrol Div, Sao Paulo, SP - Brazil
Total Affiliations: 2
|
| Document type: | Review article |
| Source: | EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES; v. 40, n. 5 JAN 2021. |
| Web of Science Citations: | 6 |
| Abstract | |
COVID-19 pandemic is caused by the novel coronavirus SARS-CoV-2. Angiotensin-converting enzyme 2 (ACE2) is not only an enzyme but also a functional receptor on cell surfaces through which SARS-CoV-2 enters the host cells and is highly expressed in the heart, kidneys, and lungs and shed into the plasma. ACE2 is a key regulator of the renin-angiotensin-aldosterone system (RAAS). SARS-CoV-2 causes ACE/ACE2 balance disruption and RAAS activation, which leads ultimately to COVID-19 progression, especially in patients with comorbidities, such as hypertension, diabetes mellitus, and cardiovascular disease. Therefore, ACE2 expression may have paradoxical effects, aiding SARS-CoV-2 pathogenicity, yet conversely limiting viral infection. This article reviews the existing literature and knowledge of ACE2 in COVID-19 setting and focuses on its pathophysiologic involvement in disease progression, clinical outcomes, and therapeutic potential. (AU) | |
| FAPESP's process: | 17/23195-2 - Mesenchymal stem cell therapy for halting the progression of acute and chronic kidney injury and in vivo modulate kidney-derived c-Kit stem cells |
| Grantee: | Érika Bevilaqua Rangel |
| Support Opportunities: | Regular Research Grants |